The VeriDose® CYP2D6 CNV Panel is an advanced pharmacogenomic assay designed for the accurate detection of CYP2D6 copy number variations (CNVs), including complex hybrid alleles that are often missed by conventional methods. This innovative single-well test analyzes seven key regions of the CYP2D6 gene, delivering comprehensive coverage in one efficient run.
Optimized for use in clinical chemistry and molecular diagnostics, the panel enables laboratories to confidently classify metabolizer status—essential for personalized drug therapy. Fully compatible with Agena’s genotyping panels, the VeriDose® CNV Panel integrates seamlessly into existing PGx workflows, providing a streamlined, cost-effective solution for complete CYP2D6 profiling.
The VeriDose® CYP2D6 CNV Panel by Agena Bioscience™ is a highly advanced molecular assay designed to detect copy number variations (CNVs) across seven key regions of the CYP2D6 gene. In a single-well format, it interrogates 22 distinct loci commonly associated with clinically significant CYP2D6 variants, enabling simultaneous detection of CNVs and hybrid alleles. This streamlines complex pharmacogenomic workflows, increasing both accuracy and efficiency.
The panel is designed to work in tandem with Agena’s genotyping assays, delivering a dual-layer PGx solution that combines CNV and SNP analysis in one integrated process.
The CYP2D6 enzyme metabolizes approximately 25% of commonly prescribed drugs, including antidepressants, beta-blockers, and opioids. Structural variations—such as gene deletions, duplications, and hybrid alleles like *13, *68, or exon 9 rearrangements—can dramatically impact a patient’s drug response:
Ultra-rapid metabolizers (due to duplications) may require lower dosages to avoid toxicity.
Poor metabolizers (due to deletions or non-functional hybrids) may not respond to treatment at all.
Hybrid alleles are particularly complex and underdetected—affecting up to 45% of individuals in certain populations—making accurate identification essential for safe and effective drug therapy.
Comprehensive Gene Coverage
Targets seven key regions of the CYP2D6 gene, including areas prone to hybrid formation, minimizing the risk of misclassification.
Hybrid Allele Detection
Identifies clinically relevant hybrid alleles that many standard CNV tests miss.
Single-Well Workflow
Reduces hands-on time and pipetting errors, improving lab efficiency.
Seamless Integration
Works alongside Agena’s genotyping panels for a full pharmacogenomic profile (CNVs + SNPs).
Streamlined Testing
Eliminates the need for reflex testing or multiple assays, consolidating results into one run.
DNA extraction from the patient sample
Single-well amplification using the CYP2D6 CNV Panel
CNV and hybrid allele detection via mass spectrometry
Data interpretation through integrated software aligned with genotyping results
This unified approach gives laboratories a complete view of a patient’s CYP2D6 copy number and SNP profile, in one workflow.
The CYP2D6 CNV Panel contributes directly to personalized medicine by enabling precise determination of metabolizer status—from poor to ultra-rapid. This allows healthcare providers to tailor drug regimens for:
Improved safety
Increased efficacy
Reduced treatment costs
It is especially impactful in specialties such as:
Psychiatry
Cardiology
Pain management
Furthermore, by detecting hybrid alleles often missed in traditional testing, the panel ensures equitable and accurate pharmacogenomic results across ethnically diverse populations.
Ideal for:
Clinical diagnostics labs
Translational research centers
Pharmaceutical clinical trial teams
Routine PGx screening programs
The VeriDose® CYP2D6 CNV Panel represents a leap forward in pharmacogenomic testing. Its accurate detection of CNVs and hybrid alleles, combined with an efficient, single-well workflow, positions it as a vital tool for any lab embracing the future of precision medicine.
Brochure
For any missing information or if you require additional details, please do not hesitate to contact us.
Subscribe to our newsletter.